COMP <GO>
XENE vs JNJ // RSI-14 & 200D SMA MOMENTUM
Xenon Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: XENE 3
— JNJ 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $37.41 (-0.35%) • MKT CAP: $3.64B
rsi-technicals
44.3
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | 2.97% | -10.67 | JNJ | /fcf-yield <GO> |
| Operating Margin | -36.70% | 34.70% | -71.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 28.50% | -62.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 6.00% | +1.70 | XENE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 44.3 | 60.4 | -16.07 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | XENE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 23.0x | +6.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $662.49B | -$658.86B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | JNJ REV | XENE GROSS % | JNJ GROSS % | XENE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$279.9M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$184.5M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$151.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
JNJ // BETA 1.08